Kath joined Brandon Capital in 2016.
Prior to joining, Katherine was based in academia working in the field of experimental stroke. She spent 5 years at Weill Cornell Medicine-New York Presbyterian Hospital as a NHMRC CJ Martin and American Australian Association Sir Keith Murdoch fellow where she focused on the impact of progranulin deficiency – a known cause of certain subtypes of dementia – on cerebral vascular integrity and susceptibility to stroke.
Upon her return to Australia Katherine joined the Florey Institute of Neuroscience and Mental Health and began establishing herself as an independent researcher. During her time in academia she published multiple research articles in top tier journals including J Neurosci, Stroke, Mol Psych and Nature Communs and secured competitive research funding from both the NHMRC and Brain Foundation of Australia.
Kath is a Director of NRG Therapeutics. and board observer of Allay Therapeutics and AstronauTx.
Kath has a Bachelor of Science (First-class Honours) from The University of Melbourne, a PhD in Pharmacology from The University of Melbourne and an MBA (Deans’ Honours list) from the Melbourne Business School, having received Dean’s commendations in macroeconomics, business law, operations and entrepreneurship. Kath is a graduate of the Australian Institute of Company Directors.